


Correction

Article on RAV12 antibody, oncosis, and antitumor activity

In the article on RAV12 antibody, oncosis, and antitumor activity in the March 2007 (1) issue, some of the data in part E of Fig. 5 appeared incorrectly. The corrected Fig. 5 appears below.



Reference

1. Loo D, Pryer N, Young P, Liang T, Coberly S, King KL, Kang K, Roberts P, Tsao M, Xu X, Potts B, Mather JP. The glycotope-specific RAV12 monoclonal antibody induces oncosis *in vitro* and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts *in vivo*. *Mol Cancer Ther* 2007;6:856 - 65.

Molecular Cancer Therapeutics

Article on RAV12 antibody, oncosis, and antitumor activity

Mol Cancer Ther 2007;6:1682.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/6/5/1682>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://mct.aacrjournals.org/content/6/5/1682.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/6/5/1682>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.